details

Peer companies

;

Share Market News

The Revenue for the quarter ended  December 2019 of Rs. 165.58 millions grew by 9.06 % from Rs. 151.83 millions.Net profit for the quarter ended December 2019 increased significantly by 81.21% to Rs. 39.34 millions from Rs. 21.71 millions.The company reported a good operating profit of 75.75 millions compared to 52.19 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201912 201812 % Var 201912 201812 % Var 201903 201803 % Var Sales 165.58 151.83 9.06 529.66 528.90 0.14 738.31 912.57 -19.10 Other Income 24.78 18.06 37.21 72.87 52.01 40.11 73.37 30.13 143.51 PBIDT 75.75 52.19 45.14 256.49 221.62 15.73 332.84 362.98 -8.30 Interest 15.44 17.64 -12.47 61.76 69.13 -10.66 86.56 66.85 29.48 PBDT 60.31 34.55 74.56 194.73 152.49 27.70 246.28 296.13 -16.83 Depreciation 3.16 2.87 10.10 8.85 8.39 5.48 11.44 9.28 23.28 PBT 57.15 31.68 80.40 185.88 144.10 28.99 234.83 286.85 -18.13 TAX 17.81 9.97 78.64 49.36 44.11 11.90 66.49 86.52 -23.15 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 39.34 21.71 81.21 136.52 99.99 36.53 168.34 200.33 -15.97 Equity 104.11 104.11 0.00 104.11 104.11 0.00 104.11 104.11 0.00 PBIDTM(%) 45.75 34.37 33.09 48.43 41.90 15.57 45.08 39.78 13.34

The sales moved down -39.97% to Rs. 180.84 millions for the September 2018 quarter as compared to Rs. 301.25 millions during the corresponding quarter last year.The Company to register a -52.63%  fall in the net profit for the quarter ended September 2018.Operating Profit reported a sharp decline to 80.30 millions from 122.00 millions in the corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201803 201703 % Var Sales 180.84 301.25 -39.97 388.11 501.44 -22.60 912.57 753.98 21.03 Other Income 19.33 4.59 321.13 33.96 9.59 254.12 30.13 15.43 95.27 PBIDT 80.30 122.00 -34.18 180.93 187.70 -3.61 362.98 257.66 40.88 Interest 23.74 10.32 130.04 51.49 19.55 163.38 66.85 25.37 163.50 PBDT 56.56 111.68 -49.36 129.44 168.15 -23.02 296.13 232.29 27.48 Depreciation 2.84 2.29 24.02 5.52 4.18 32.06 9.28 7.58 22.43 PBT 53.73 109.39 -50.88 123.93 163.98 -24.42 286.85 224.71 27.65 TAX 12.69 22.75 -44.22 34.14 40.53 -15.77 86.52 75.61 14.43 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 41.04 86.64 -52.63 89.79 123.44 -27.26 200.33 149.10 34.36 Equity 104.11 104.11 0.00 104.11 104.11 0.00 104.11 104.11 0.00 PBIDTM(%) 44.41 40.50 9.66 46.62 37.43 24.54 39.78 34.17 16.39

A slight decline in the revenue of Rs. 247.80 millions was seen for the December 2017 quarter as against Rs. 252.02 millions during year-ago period.Net Profit witnessed a 115.52% growth almost the double from Rs. 29.96 millions to Rs. 64.57  millions  of same quarter last year.The company reported a good operating profit of 119.89 millions compared to 55.46 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 247.80 252.02 -1.67 754.19 572.63 31.71 753.98 436.51 72.73 Other Income 8.14 3.39 140.12 17.73 10.61 67.11 15.43 18.04 -14.47 PBIDT 119.89 55.46 116.17 312.54 179.68 73.94 257.65 119.56 115.50 Interest 19.67 5.74 242.68 39.22 19.07 105.66 25.37 19.74 28.52 PBDT 100.22 49.72 101.57 273.32 160.61 70.18 232.28 99.82 132.70 Depreciation 2.26 1.47 53.74 6.44 5.44 18.38 7.58 9.19 -17.52 PBT 97.96 48.25 103.03 266.88 155.09 72.08 224.71 90.63 147.94 TAX 33.39 18.30 82.46 73.93 54.87 34.74 75.61 30.57 147.33 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 64.57 29.96 115.52 192.96 100.23 92.52 149.10 60.06 148.25 Equity 104.11 104.11 0.00 104.11 104.11 0.00 104.11 104.11 0.00 PBIDTM(%) 48.38 22.01 119.86 41.44 31.38 32.07 34.17 27.39 24.77

Arihant Capital Markets has informed that the Company has fixed March 18, 2016 as the Record Date for the purpose of Payment of Interim Dividend, if declared.The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets has informed that a meeting of the Board of Directors of the Company will be held on March 10, 2016, to consider and declaration of Interim Dividend for the F.Y. 2015-16. Further, for the above purpose and as per the Company’s Internal Code of Conducts for Prevention of insider Trading, the Trading Window for dealing in the securities of the Company will remain close for Specified Persons from March 05, 2016 till the completion of 48 hours from the results are made available to public on March 10, 2016.The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets has informed about Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets (‘Manager to the Offer’) on behalf of Ipca Laboratories Limited (‘Acquirer’) has informed this Corrigendum to the DPS in respect of the Open Offer to the Equity Shareholders of Krebs Biochemicals and Industries (‘Target Company’) pursuant to and in compliance with Regulation 3(1) and (4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto (‘SEBI SAST Regulations’). This Corrigendum is being issued pursuant to changes / amendments advised by SEBI vide their letter dated October 21, 2015 and should be read in conjunction with the DPS published on February 24, 2015 in publications. The terms used in this Corrigendum to the DPS have the same meaning assigned to them in the DPS issued earlier, unless otherwise specified.The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets has informed that the meeting of the Board of Directors of the Company will be held on November 07, 2015, to consider and take on record the Un-audited Financial Results for the quarter and half year ended on September 30, 2015. Further, for the above purpose and as per the Company’s Internal Code of Conducts for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will remain close for Specified Persons from October 29, 2015 to after 48 hours the results are made available to public on November 07, 2015.The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets (‘Manager to the Buyback Offer’) has submitted a copy of post buy back public announcement (‘PA’) to the Equity Shareholders/ beneficial owners of the Equity Shares of Span Diagnostics (‘Target Company’) in pursuant to Regulation 19(7) of the Securities and Exchange Board of India (Buy-back of Securities ) Regulations, 1998, as amended, (‘SEBI Buyback Regulations’).The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets (‘Manager to the Buyback Offer’) has submitted a copy of Corrigendum to Public Announcement dated August 08, 2015 published on August 10, 2015 and the Letter of Offer dated September 16, 2015 to the Shareholders/ beneficial owners of Equity Shareholders of Span Divergent (Formerly Known as Span Diagnostics Ltd).The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets has submitted a copy of the Minutes of the 23rd Annual General Meeting of the members of the Company held on August 08, 2015.The above information is a part of company’s filings submitted to BSE.

Arihant Capital Markets has informed that the Register of Members & Share Transfer Books of the Company will remain closed from August 01, 2015 to August 08, 2015 for the purpose of Payment of Dividend & 23rd Annual General Meeting (AGM) of the Company to be held on August 08, 2015.The above information is a part of company’s filings submitted to BSE.